The management of women at high risk of experiencing hereditary breast and ovarian cancer: The lahey guidelines

Disease Management and Health Outcomes

Volumn 7, Issue 4, 2000, Pages 201-215

  Hughes, Kevin S ^a   Roche, Constance A ^a   Whitney, Timothy ^a   McLellan, Robert ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; OVARY CANCER; REVIEW;

EID: 0034090866     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200007040-00004     Document Type: Review

References (50)

1. 1. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993; 25: 113-8
2. 2. Burke W, Duly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCAI and BRCA2. Cancer Genetics Study Consortium. JAMA 1997 Mar 26; 277 (12): 997-1003
3. 3. Hughes KS, Papa MZ, Whitney T, et al. Prophylactic surgery and inherited cancer predisposition. In: Shall GL, editor. Cancer genetics for the clinician. New York: Plenum Publishing Corporation. In press
4. 4. Smith SA, Easton DF, Evans DG, et al. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992 Oct; 2 (2): 128-31
5. 5. Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973-1995. Bethesda (MD): National Cancer Institute, 1998
6. 6. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993 Apr; 52 (4): 678-701
7. 7. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995 Jan; 56 (1): 265-71
8. 8. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BKCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994 Mar 19; 343 (8899): 692-5
9. 9. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995 Oct; 72 (4): 805-12
10. 10. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997 May 15; 336 (20): 1401-8
11. IL Roche CA, Lucas MR, Hughes KS. Development of a risk assessment clinic. In: Management of women at high risk for breast cancer. Oxford: Blackwell Science, Inc. In press
12. 12. Lahey Clinic Risk Assessment Clinic Web Site [online]. Available from: URL: http://www.familycancer.org [Accessed 1999 Sep 1]
13. 13. Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society Guidelines for the early detection of breast cancer: update 1997. California: American Cancer Society, 1997
14. 14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998 Sep 16; 90 (18): 1371-88
15. 15. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992 Oct; 80 (4): 708-14
16. 16. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994 Mar; 83 (3): 419-24
17. 17. Foulkes WD, Wong N, Brunet JS, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997 Dec; 3 (12 Pt 1): 2465-9
18. 18. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998 Jan 31; 351 (9099): 316-21
19. 19. Johannsson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study form southern Sweden. J Clin Oncol 1998 Feb; 16 (2): 397-404
20. 20. Crook T, Crossland S, Crompton MR, et al. p53 mutations in BRCA1-associated familial breast cancer |letter). Lancet 1997 Aug 30; 350 (9078): 638-9
21. 21. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997 May 24; 349 (9064): 1505-10
22. 22. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989 Jan; 4 (1): 1-12
23. 23. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992 Jul; 80 (1): 14-8
24. 24. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994 Jul 15; 121 (2): 124-32
25. 25. van Nagell Jr JR, Higgins RV, Donaldson ES, et al. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1,000 cases screened. Cancer 1990 Feb; 65 (3): 573-7
26. 26. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998 Jul 11; 352 (9122): 98-101
27. 27. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998 Jul 11; 352 (9122): 93-7
28. 28. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14 (1): 103-10
29. 29. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998 Aug 13; 339 (7): 424-8
30. 30. Stadel BV, Rubin GL, Webster LA, et al. Oral contraceptives and breast cancer in young women. Lancet 1985 Nov 2; II (8462): 970-3
31. 31. Struewing JP, Watson P. Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst Monogr 1995; 17: 33-5
32. 32. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991 Oct; 14: 451-4
33. 33. Goodnight Jr JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984 Jul; 26 (3): 198-201
34. 34. Bowers Jr DG, Radlauer CB. Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 1969 Dec; 44 (6): 541-4
35. 35. Mendez-Fernandez MA, Henly WS, Geis RC, et al. Paget's disease of the breast after subcutaneous mastectomy and reconstruction with a silicon prosthesis. Plast Reconstr Surg 1980 May; 65 (5): 683-5
36. 36. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984 Nov; 148 (5): 692-3
37. 37. Jameson MB, Roberts E, Nixon J, et al. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. Clin Oncol (R Coll Radiol) 1997; 9 (2): 119-21
38. 38. Humphrey LJ. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: opinion or knowledge? Am J Surg 1983 Mar; 145 (3): 311-2
39. 39. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989 Winter; 13 (1): 15-21
40. 40. Woods JE, Meland NB. Conservative management in full-thickness nipple-areolar necrosis after subcutaneous mastectomy. Plast Reconstr Surg 1989 Aug; 84 (2): 258-6
41. 41. Slade CL. Subcutaneous mastectomy: acute complications and long-term follow-up. Plast Reconstr Surg 1984 Jan; 73 (1): 84-90
42. 42. Fredericks S. A 10-year experience with subcutaneous mastectomy. Clin Plast Surg 1975 Jul; 2 (3): 347-57
43. 43. Amaaki T, Yasumura K, Kami T, et al. Prophylactic subcutaneous total glandectomy for mammary cystic disease, with immediate primary breast reconstruction. Ann Plast Surg 1979 Nov; 3 (5): 420-4
44. 44. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999 Jan 14; 340 (2): 77-84
45. 45. Weber AM, Hewett WJ, Gajewski WH, et al. Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol 1992 Sep; 80 (3 Pt 2): 558-60
46. 46. Colditz. GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990 Nov 28; 264 (20): 2648-53
47. 47. Daly M, Angelos P, Bryant E, et al. NCCN Practice Guidelines: genetics/familial high-risk cancer screening. Oncology 1999 Nov; 13 (11A): 161-83
48. 48. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis -effects of prophylactic mastectomy and oophorectomy on life expenctancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997 May 15; 336 (20): 1465-71
49. 49. Grann VR, Panageas KS, Whang W. Decision analysis of prov phylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998 Mar; 16 (3): 979-85
50. 50. Levine A, Hughes KS. Cost-effectiveness of the identification of women at high risk for the development of breast and ovarian cancer, In: Vogel VG, editor. Management of women at high risk for breast cancer. Boston (MA): Blackwell Science, Inc. In press